SCHEMBL4025988

SCHEMBL4025988

Cn1nc(-c2ccc(O)c(O)c2)c2cc(F)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.48
KDM4C Q9H3R0 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.39
ESR1 P03372 1/20 0.38
CLK1 P49759 1/20 0.38
CLK2 P49760 1/20 0.38
DYRK1A Q13627 1/20 0.38
DYRK2 Q92630 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
KHK P50053 1/20 0.37
PTGER1 P34995 1/20 0.36
JAK3 P52333 1/20 0.36
APP P05067 1/20 0.36
SSTR4 P31391 1/20 0.36
SCN9A Q15858 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
PIK3CD O00329 1/20 0.34
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030264 0.85 NAMPT (0.53) NAMPTKDM4CL3MBTL1ESR1KHK
SCHEMBL4029746 0.84 NAMPT (0.47) NAMPTL3MBTL1ESR1KHKJAK3
SCHEMBL4026271 0.82 SCN9A (0.46) NAMPTL3MBTL1ESR1SCN9AMEN1
SCHEMBL4029614 0.80 ESR1 (0.39) NAMPTL3MBTL1ESR1JAK3APP
SCHEMBL20389257 0.79 NAMPT (0.50) NAMPTKDM4CL3MBTL1KHKPTGER1
SCHEMBL4034001 0.79 L3MBTL1 (0.59) NAMPTKDM4CL3MBTL1KHKPTGER1
SCHEMBL20389048 0.77 NAMPT (0.56) NAMPTKDM4CL3MBTL1KHKAPP
SCHEMBL5407109 0.77 ESR1 (0.67) NAMPTKDM4CESR1
SCHEMBL4031391 0.76 PDE5A (0.47) KDM4CESR1MEN1POLBKMT2A
SCHEMBL4029390 0.74 SCN9A (0.52) ESR1PTGER1SCN9ASRCMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR NAMPT 4390/4885KDM4C 673/4885L3MBTL1 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.